BioSpace

Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3

If approved, the oral GLP-1 would be Eli Lilly’s second marketed drug for obstructive sleep apnea after the GIP/GLP-1 injectable Zepbound secured the first approval in the space in December 2024.

By BioSpace

1 min read
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights